Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model

被引：14
|
作者：
Cortese, Brian D. [1 ]
Chang, Sam S. [2 ]
Talwar, Ruchika [2 ]
机构：
[1] Univ Penn Hlth Syst, Div Urol, Dept Surg, Philadelphia, PA USA
[2] Vanderbilt Univ, Dept Urol Surg, Nashville, TN USA
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷 / 02期
关键词：
Medicare Part D; health policy; drug prescriptions; drugs; generic; drug costs;
D O I：
10.1097/JU.0000000000003083
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：309 / 311
页数：3
相关论文
共 50 条
  • [21] A Systematic Review of the Costs of Drug-Associated Acute Kidney Injury and Potential Cost Savings with Nephrotoxin Stewardship Prevention Strategies
    Stottlemyer, Britney A.
    Tran, Tiffany
    Suh, Kangho
    Kane-Gill, Sandra L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024,
  • [22] Drug Treatment of Cystic Fibrosis - Cost Patterns and Savings Potential for Outpatient Treatment
    Baltin, Christoph T.
    Smaczny, Christina
    Wagner, Thomas O.
    MEDIZINISCHE KLINIK, 2010, 105 (12) : 887 - 900
  • [23] Registry-based trials: a potential model for cost savings?
    Anderson, Brett R.
    Gotlieb, Evelyn G.
    Hill, Kevin
    McHugh, Kimberly E.
    Scheurer, Mark A.
    Mery, Carlos M.
    Pelletier, Glenn J.
    Kaltman, Jonathan R.
    White, Owen J.
    Trachtenberg, Felicia L.
    Hollenbeck-Pringle, Danielle
    McCrindle, Brian W.
    Sylvester, Donna M.
    Eckhauser, Aaron W.
    Pasquali, Sara K.
    Anderson, Jeffery B.
    Schamberger, Marcus S.
    Shashidharan, Subhadra
    Jacobs, Jeffrey P.
    Jacobs, Marshall L.
    Boskovski, Marko
    Newburger, Jane W.
    Nathan, Meena
    CARDIOLOGY IN THE YOUNG, 2020, 30 (06) : 807 - 817
  • [24] Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies
    Leung, Caitlyn Y. W.
    Cheung, Matthew C.
    Charbonneau, Lauren F.
    Prica, Anca
    Ng, Pamela
    Chan, Kelvin K. W.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (07) : E646 - E652
  • [25] POTENTIAL COST SAVINGS BY PREVENTION OF ADVERSE DRUG EVENTS WITH A NOVEL MEDICATION REVIEW PROGRAM
    Fernandez, E., V
    Warriner, C. L.
    David, T. N.
    Gordon, E. A.
    Jackson, S.
    Twigg, G.
    Carroll, N., V
    VALUE IN HEALTH, 2018, 21 : S320 - S320
  • [26] Potential cost savings by prevention of adverse drug events with a novel medication review program
    Fernandez, Elena, V
    Warriner, Cindy L.
    David, Tosin
    Gordon, Elizabeth
    Twigg, Geoffrey
    Carroll, Norman, V
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (03) : 462 - +
  • [27] Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis
    Irma Convertino
    Stefano Salvadori
    Alessandro Pecori
    Maria Teresa Galiulo
    Sara Ferraro
    Maria Parrilli
    Tiberio Corona
    Giuseppe Turchetti
    Corrado Blandizzi
    Marco Tuccori
    Drug Safety, 2019, 42 : 427 - 444
  • [28] Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis
    Convertino, Irma
    Salvadori, Stefano
    Pecori, Alessandro
    Galiulo, Maria Teresa
    Ferraro, Sara
    Parrilli, Maria
    Corona, Tiberio
    Turchetti, Giuseppe
    Blandizzi, Corrado
    Tuccori, Marco
    DRUG SAFETY, 2019, 42 (03) : 427 - 444
  • [29] Serious Adverse Drug Reactions to Antipsychotics in Minors with Multiple Disabilities: Preventability and Potential Cost Savings by Therapeutic Drug Monitoring
    Fekete, Stefanie
    Guentzel, Tim
    Egberts, Karin
    Geissler, Julia
    Neubert, Antje
    Gerlach, Manfred
    Romanos, Marcel
    Taurines, Regina
    PHARMACOPSYCHIATRY, 2023, 56 (01) : 32 - 39
  • [30] The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis
    Atle Fretheim
    Morten Aaserud
    Andrew D Oxman
    BMC Health Services Research, 3
12345